Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.

导出 OA

翻译打印收藏纠错

第一作者： Feng,Xiao

第一单位： Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.

作者： Feng,Xiao ^[1] ; Ying,Li ^[1] ; Weilai,Xu ^[1] ; Liangshun,You ^[1] ; Chunmei,Yang ^[1] ; Hui,Liu ^[1] ; Wenbin,Qian ^[1]

作者单位： Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China. ^[1]

关键词 aclarubicin cytarabine high-intensity chemotherapy homoharringtonine myelodysplastic syndromes

DOI 10.3892/ol.2015.3876

PMID 26870217

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览42

Oncology letters

2016年11卷1期

355-359页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.

Oncology letters

相似文献

Oncology letters

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.

Oncology letters

相似文献

Oncology letters

相关期刊

检索历史清除